Your browser doesn't support javascript.
[How to deal with an unexpected event that could alter the normal activity of cellular therapy? Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. / Comment faire face à un événement inattendu pouvant modifier l'activité normale de thérapie cellulaire ? Recommandations de la Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
Bay, Jacques Olivier; Beguin, Yves; Carpentier, Alexandre; Dard, Céline; Guillaume, Thierry; Labussiere-Wallet, Hélène; Lacassagne, Marie Noëlle; Sauze, Séverine; Yakoub-Agha, Ibrahim; Chalandon, Yves.
  • Bay JO; CHU Clermont-Ferrand, Service de thérapie cellulaire et d'hématologie clinique adulte, 1 place Lucie Aubrac, 63000 Clermont-Ferrand, France. Electronic address: jobay@chu-clermontferrand.fr.
  • Beguin Y; CHU de Liège et Université de Liège, Service d'Hématologie, Liège, Belgique.
  • Carpentier A; Laboratoire de Thérapie Cellulaire, Tour-4E du CHU de Liège, route 1159, Domaine du Sart-Tilman, 4000 Liège, Belgique.
  • Dard C; Laboratoire d'histocompatibilité, EFS Auvergne Rhône Alpes, Site de la Tronche, 29, avenue du Maquis du Grésivaudan, 38701 La Tronche cedex.
  • Guillaume T; CHU de Nantes, Service d'hématologie clinique, Hôtel Dieu, 1, place Ricordeau, 44000 Nantes, France.
  • Labussiere-Wallet H; Hôpital Lyon Sud, Service d'hématologie clinique, Hospices Civils de Lyon, Pierre Bénite, France.
  • Lacassagne MN; Laboratoire de thérapie cellulaire CHU Amiens Picardie, 1, rond point du professeur Christian Cabrol, 80054 Amiens cedex 01, France.
  • Sauze S; CHU d'Angers, Service d'hématologie, rue Larrey, 49000 Angers, France.
  • Yakoub-Agha I; CHU de Lille, Université Lille, Inserm U1286, Infinite, 59000 Lille, France.
  • Chalandon Y; Hôpitaux Universitaires de Genève et Faculté de Médecine, Université de Genève, Service d'hématologie, département d'oncologie, Genève, Suisse.
Bull Cancer ; 108(12S): S20-S25, 2021 Dec.
Article in French | MEDLINE | ID: covidwho-1293624
ABSTRACT
The SARS-CoV-2 (COVID-19) pandemic has rapidly impacted cell therapy activities across the globe. Not only was this, unexpected event, a threat to patients who had previously received hematopoietic cell transplantation or other cell therapy such as CAR-T cells, but also, it was responsible for a disruption of cell therapy activities due to the danger of the virus and to the lack of solid scientific data on the management of patients and donors. The Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) devoted a workshop to issue useful recommendations in such an unexpected event in order to harmonize the actions of all the actors involved in cellular therapy programs so that we can collectively face, in the future, the challenges that could threaten our patients. This work is not specifically dedicated to the SARS-CoV-2 outbreak, but the latter has been used as a concrete example of an unexpected event to build up our recommendations.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Bone Marrow Transplantation / Cell Transplantation / Pandemics / COVID-19 Type of study: Observational study Limits: Humans Language: French Journal: Bull Cancer Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Bone Marrow Transplantation / Cell Transplantation / Pandemics / COVID-19 Type of study: Observational study Limits: Humans Language: French Journal: Bull Cancer Year: 2021 Document Type: Article